# Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-risankizumab-in-moderate-to-severe-plaque-psoriasis/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Kenneth B. Gordon,Bruce Strober,Mark Lebwohl,Matthias Augustin,Andrew Blauvelt,Yves Poulin,Kim Papp,Howard Sofen,L. Puig,Peter Foley,Mamitaro Ohtsuki,Mary Flack,Ziqian Geng,Yihua Gu,Joaquin Valdes,Elizabeth H. Thompson,H. Bachelez |
| Citations | 669 |
| DOI | 10.1016/s0140-6736(18)31713-6 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2887412253 |
| PMID | 30097359 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Matthias Augustin](https://scholariq.org/researchers/matthias-augustin/)
- [Bruce Strober](https://scholariq.org/researchers/bruce-strober/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)

## Paper topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.